Difference between revisions of "Aminocaproic acid (Amicar)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
m (updated content) |
||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Inhibits fibrinolysis by inhibiting plasminogen activators and via antiplasmin activity.<ref name="insert">[http://products.hospira.com/assets/pdfs/EN-1485.pdf Aminocaproic acid (Amicar) package insert]</ref><ref>[ | + | Class/mechanism: Inhibits fibrinolysis by inhibiting plasminogen activators and via antiplasmin activity.<ref name="insert">[http://products.hospira.com/assets/pdfs/EN-1485.pdf Aminocaproic acid (Amicar) package insert]</ref><ref>[[Media:Aminocaproicacid.pdf | Aminocaproic acid (Amicar) package insert (locally hosted backup)]]</ref><ref>[[Media:Aminocaproicacidtablets.pdf | Aminocaproic acid tablets (Amicar) package insert (locally hosted backup)]]</ref> |
<br>Route: IV, PO | <br>Route: IV, PO | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
Revision as of 02:27, 7 October 2012
Also known as 6-aminohexanoic acid, epsilon aminocaproic acid, ε-aminocaproic acid, ε-Ahx.
General information
Class/mechanism: Inhibits fibrinolysis by inhibiting plasminogen activators and via antiplasmin activity.[1][2][3]
Route: IV, PO
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]